// App-Quantinova.ai

: nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.

Researchers

Presenter

  • Timothy Jay Price

Principal Investigators

  • Leslie Mi Ok Chong

  • Nicholas Ede

  • Bonnie Nixon

  • Nimali Withana

  • Sharon Yavrom

  • Giovanni Selvaggi

  • Anthony J. Good

Medical Centers

  • Engeneic, Sydney, Australia

  • The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • Programmed cell death 1 ligand 2

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • T cell receptor alpha locus

Drug/Treatment

  • Peptide vaccine

  • Pembrolizumab

  • Trastuzumab

  • Ramucirumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Open Label

  • Non-Comparative

Phase

  • II

Study Id's

  • NCT05311176

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved